Research Officer, Protagonist Therapeutics
Institute for Molecular Bioscience, The University of Queensland
The Institute’s 500 scientists, support staff and postgraduate students from more than 40 countries are working to improve quality of life for all. IMB has three major divisions and four research centres. IMB’s multidisciplinary research programs focus on advancing medical genomics, drug discovery and biotechnology. By investigating the basis of growth and development at the genetic, molecular, cellular and organ level, our researchers aim to better understand the development processes and pathways involved in human and animal health and disease. They also work to translate these findings into diagnostics; technologies and therapeutics to more effectively prevent, detect and treat disease, and deliver a sustainable future for Australia through initiatives such as clean energy and new agricultural compounds.
IMB is equipped with state-of-the-art research infrastructure including mouse and zebrafish facilities, advanced imaging and microarray platforms, high-throughput sequencing, advanced bioinformatics and proteomics – all of which support the Institute’s leading life sciences research. Details of the research interests of the Institute may be accessed on the Institute’s website at: http://www.imb.uq.edu.au.
Protagonist Therapeutics Pty Ltd
Protagonist Therapeutics is an Australian and U.S.-incorporated biotechnology company, pursuing the discovery and development of disulfide-rich peptides (DRPs) as well as differentiated alternatives to biologics, and as new chemical entities (NCEs) against those targets and life threatening diseases for which ideal small molecule and/or biologic options are unavailable. DRPs are a proven chemical class of drugs with numerous examples of orally stable and injectable NCEs on the market and in various stages of clinical development. The company has a validated technology platform well suited to explore the full potential of the DRP scaffold class. It comprises of a purposefully built computational design environment, directed evolution approaches to prepare millions of molecules via phage libraries, and classical small molecule medicinal chemistry-type analoging and SAR development.
Protagonist Therapeutics is a spin-out of the University of Queensland’s Institute of Molecular Biosciences (IMB) and has discovery operations in Brisbane, Queensland, Australia and Newark, California USA. For further information, visit http://www.protagonist-inc.com
Protagonist Therapeutics is seeking a talented and highly motivated scientist to be involved in its broad discovery efforts utilising their experience in Medicinal and Peptide chemistry. The individual will be involved in the company’s target-specific drug discovery efforts through the synthesis and biochemical analysis of compounds directed at clinically relevant targets.
The successful candidate will ideally have strong peptide and organic chemistry background with both solution and solid phase experience. Ideally, the candidate will have a PhD, although someone with experience will also be accepted. Experience with strong bioanalytical methods (LC MSMS) will be looked upon favourably. The position is based in Brisbane, Australia.
The University of Queensland values diversity and inclusion.
Applications are particularly encouraged from Aboriginal and Torres Strait Islander peoples. For further information please contact our Australian Indigenous Employment Coordinator at: firstname.lastname@example.org
Applications are also encouraged from women.
This is a full-time, fixed term appointment at Academic level A. The remuneration package will be in the range $64,533.50- $87,535.13 p.a., plus employer superannuation contributions of up to 17% (total package will be in the range $75,504.20 - $102,416.10 p.a.).
To discuss this role please contact Gregory Bourne email@example.com or 07 3346 2976.
To submit an application for this role, use the Apply button below. All applicants must supply the following documents: Cover letter, Resume and Selection Criteria responses.
For information on completing the application process click here.
Applications Close 20 March 2018 at 5pm AEST